drug

AL002

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about AL002: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

18Connections

0Hypotheses

12Analyses

17Outgoing

1Incoming

0Experiments

18Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💊 Drug Info

Name	AL002
Key Genes/Proteins	Trem2, TREM2
Related Diseases	Alzheimer disease, Alzheimer disease cognitive benefit, Alzheimer's disease, Alzheimer's_disease, Alzheimer's Disease (early stage)

Pathway Diagram

flowchart TD
    AL002{"AL002"}
    TREM2(["TREM2"])
    microglia["microglia"]
    CEREBROSPINAL_FLUID("CEREBROSPINAL FLUID")

    AL002 -->|"expressed in"| TREM2
    AL002 -->|"activates"| microglia
    AL002 -.->|"inhibits"| microglia
    AL002 -->|"associated with"| TREM2
    AL002 -->|"associated with"| CEREBROSPINAL_FLUID

    style AL002 fill:#1a237e,stroke:#4fc3f7,stroke-width:3px,color:#fff

Outgoing (17)

Target	Relation	Type	Str
TREM2	targets	gene	0.90
Alzheimer disease cognitive benefit	therapeutic_target_for	phenotype	0.90
Alzheimer's Disease (early stage)	targets	disease	0.90
TREM2	modulates	protein	0.90
Alzheimer's_disease	targets	disease	0.70
TREM2	therapeutic_target_for	gene	0.70
Alzheimer's disease	therapeutic_target_for	disease	0.70
Alzheimer disease	therapeutic_target_for	disease	0.70
TREM2	activates	gene	0.70
early Alzheimer disease	therapeutic_target_for	disease	0.70
Trem2	regulates	protein	0.70
Tau Propagation	targets	phenotype	0.70
microglia	activates	cell_type	0.50
microglia	inhibits	cell_type	0.50
CEREBROSPINAL FLUID	associated_with	concept	0.50
TREM2	expressed_in	gene	0.50
TREM2	associated_with	gene	0.50

Incoming (1)

Source	Relation	Type	Str
DENALI BBB shuttle technology	modulates	drug	0.90

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (12)

Scientific analyses that reference this entity

TREM2 in Alzheimer's Disease: Mechanisms, Therapeutics, and Biomarkers

neurodegeneration | 2026-04-26 | 8 hypotheses Top: 0.861

scRNA-seq Processing and Cell Type Annotation of AD Brain

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.618

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.629

Does APOE4 drive tau propagation

neurodegeneration | 2026-04-15 | 0 hypotheses

How does APOE4's beneficial immune function reconcile with its established role

neurodegeneration | 2026-04-14 | 0 hypotheses

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (18)

Multi-agent debates referencing this entity

Extended debate: TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegenera

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Hypothesis debate: TREM2-Mediated Microglial Dysfunction Disrupts Perivascular T

closed · Rounds: 4 · Score: 0.50 · 2026-04-27

Hypothesis debate: TREM2-Dependent Microglial Senescence Transition

closed · Rounds: 4 · Score: 0.64 · 2026-04-26

Hypothesis debate: TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegene

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

What are the key mechanistic, therapeutic, and diagnostic dimensions of TREM2 in

closed · Rounds: 4 · Score: 0.92 · 2026-04-26

The debate proposed biphasic TREM2 modulation but couldn't define when to switch

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

The debate proposed temporal TREM2 modulation but couldn't define when to switch

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

What is the current clinical trial landscape for AD therapeutics, and which mech

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

Can standardized scRNA-seq processing and automated annotation identify novel ce

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

All participants agreed that transcriptomic vulnerability signatures don't estab

closed · Rounds: 4 · Score: 0.50 · 2026-04-20

Related Research

Hypotheses and analyses mentioning AL002 in their description or question text

No additional research found